Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Marginal effect of clean energy, nuclear energy-related R&D investment, energy security risk, and policy uncertainty on the environment in the USA.

Scientific reports·2026

Same author

Comparative analysis of acute coronary syndrome outcome: immigrants vs. residents in a monocentric STEMI network.

Journal of cardiovascular medicine (Hagerstown, Md.)·2025

Same author

Gastrointestinal Electrical Stimulation as Prevention of Postoperative Ileus-A Blinded Randomized Controlled Porcine Trial.

Neurogastroenterology and motility·2025

Same author

CUPID: A free drug discovery platform for the explainable multi-ion channel assessment of cardiotoxicity.

European journal of medicinal chemistry·2025

Same author

Biomarker profiles that differentiate type-1 and type 2 myocardial infarction.

Heart & lung : the journal of critical care·2025

Same author

Sex-mediated effects of transglutaminase 2 inhibition on endothelial function in human resistance arteries from diabetic and non-diabetic patients.

Clinical science (London, England : 1979)·2024

Search research articles

Related Experiment Video

Updated: Apr 14, 2026

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Published on: January 20, 2019

Breast carcinosarcoma: clinical and pathological features.

Marco Mele¹, Lisbeth L Jensen², Pernille Vahl²

¹Breast and Endocrinal Surgery Department, Aarhus University Hospital, Aarhus, Denmark.

|April 18, 2015

Summary

Carcinosarcoma of the breast, a rare and aggressive tumor, presents unique diagnostic challenges. This case highlights a metaplastic cell population within the tumor, emphasizing the need for careful pathological evaluation.

Keywords:

Breast carcinosarcoma

More Related Videos

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: Apr 14, 2026

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Orthotopic Injection of Breast Cancer Cells into the Mice Mammary Fat Pad

Published on: January 20, 2019

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Area of Science:

Oncology
Pathology
Surgical Oncology

Background:

Carcinosarcoma of the breast is an exceptionally rare and aggressive malignancy.
It is characterized by the presence of both epithelial (carcinomatous) and mesenchymal (sarcomatous) malignant cell components.
Existing literature on breast carcinosarcoma is notably sparse, indicating a need for further case reporting and research.

Observation:

This report details an extremely rare case of breast carcinosarcoma.
The tumor exhibited a small but significant fraction of pancytokeratin-positive, sarcomatous-appearing cells, identified as a metaplastic cell population.
This finding presents a diagnostic nuance in classifying carcinosarcomas.

Findings:

The presence of a metaplastic cell population within breast carcinosarcoma is a key pathological observation.
Pancytokeratin positivity in sarcomatous-appearing cells suggests a complex cellular origin or differentiation.
Accurate identification of both malignant components is crucial for appropriate classification.

Implications:

This case underscores the importance of comprehensive pathological assessment in diagnosing rare breast tumors.
Understanding the cellular heterogeneity in carcinosarcoma can inform treatment strategies.
Further research into the pathogenesis and behavior of metaplastic components in breast carcinosarcoma is warranted.